louisiana glp-1 gastroparesis class action First lawsuit for weight loss, diabetes drugs Mounjaro, Ozempic glp-1 gi obstruction lawsuit in

10.2307/3578091 [DOI] [PubMed] [Google Scholar] 54.Dethlefsen LA, Lehman CM, Biaglow JE, Peck VM

However, the recent FDA approvals of Wegovy (2021) and Zebound (2023) for weight loss have been met with a tremendous increase in demand for these drugs

However, the metabolic advantages (improved insulin sensitivity, enhanced fat oxidation) will diminish over time without continued use

2022;66:e00308-22

Due to the co-occurrence of migraine and gastrointestinal (GI) disorders, this issue has received more attention

Participants also were far more likely to lose at least 5%, 10%, 15%, or 20% of their body weight with semaglutide